Integer Holdings

Integer Holdings Corp. engages in the manufacture and development of medical devices and components. It operates through the Medical and Non-Medical segments. The Medical segment includes the cardio and vascular, cardiac and neuromodulation, surgical, orthopedics, and portable medical product lines. The Non-Medical segment comprises customized battery power and management systems, charging and docking stations, and power supplies. The company was founded by Wilson Greatbatch in 1970 and is headquartered in Plano, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Integer Holdings reports robust Q4 performance and optimistic 2023 outlook

Integer Holdings' strong Q4 performance, strategic financial decisions, and optimistic 2023 outlook position the company for continued growth. Despite challenges such as supply chain issues, the company remains focused on expanding margins and driving above-market sales growth. Opportunities lie in product development, acquisitions, and efficient debt management.

Integer Holdings reports strong Q1 performance amidst growth challenges

Integer Holdings' Q1 2023 performance showcased robust sales growth and improved operating income, underpinned by recovery from delayed shipments and strong demand. The company faces challenges from supply chain disruptions and direct labor turnover but is focused on margin improvement and profit growth acceleration.
With a positive pricing environment and a pragmatic approach to challenges, Integer Holdings aims to leverage its strong product development sales and targeted organic growth to outperform the market. Managing financial pressures effectively will be crucial for sustaining growth investments and financial stability.
Overall, Integer Holdings' strategic focus on operational efficiency, market leadership through innovation, and long-term resilience positions it well to navigate challenges and capitalize on growth opportunities in the evolving healthcare industry.

Integer Holdings reports robust Q2 results and raises full-year outlook

Integer Holdings delivered strong Q2 results, showcasing robust sales growth and operational performance driven by customer demand and supply chain enhancements.
The company raised its full-year outlook, emphasizing strategic growth, margin expansion, and commitment to customer satisfaction, indicating confidence in sustained growth.
While facing challenges related to market dynamics and operational efficiency, Integer Holdings remains well-positioned to capitalize on opportunities for revenue growth and value creation.
By focusing on customer-centric strategies, operational excellence, and strategic initiatives, Integer Holdings aims to drive sustainable growth and profitability in the evolving market landscape.

Integer Holdings reports strong Q3 performance and eyes growth opportunities

Integer Holdings showcased robust financial performance in Q3, driven by strong organic sales growth and improved operating income.
While facing challenges in debt management and operational integration, the company remains well-positioned in key product lines and growth areas.
With a positive outlook for 2023 and beyond, Integer Holdings is strategically focused on capitalizing on growth opportunities and maintaining financial strength.

Integer Holdings reports strong 2023 performance and growth strategies

Integer Holdings is poised for continued growth in 2024, with a focus on acquisitions, margin expansion, and operational efficiency.
Challenges include tax-related impacts, customer inventory adjustments, and the CRM segment's growth trajectory.
Opportunities lie in strategic acquisitions, margin improvement initiatives, and the strong performance of the Neuromodulation segment.

Integer Holdings reports robust Q1 performance, eyes continued growth

Integer Holdings delivered strong financial performance in Q1 2024, with sales, operating income, and EPS showing significant growth. Despite challenges in meeting the initial profit growth target, the company remains optimistic about its growth prospects and aims to enhance shareholder value through strategic execution.

Integer Holdings excels in Q2, raises profit outlook for 2024

Integer Holdings delivered a strong Q2 performance with sales, operating income, and EPS showing significant growth. The company's financial health remains robust, with a positive outlook for the full year and opportunities for continued growth and profitability.

Integer Holdings excels in Q3, focuses on medical tech growth

Integer Holdings reported strong financial performance in Q3 2024, with notable sales and operating income growth. The company's strategic divestment, improved financial outlook, and focus on medical technology highlight a clear path for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ABIOMED

Abbott Labs

IDEXX Laboratories

Teleflex

Earnings and revenues for the Medical Instruments sector in the third quarter are likely to have declined sequentially. Read to know how a few companies from the sector might have fared in the period.

Medical Instruments' Oct 31 Earnings Roster: IDXX, ABMD & More

Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Integer (ITGR) Reports Next Week: What to Expect

Integer Holdings' (ITGR) buyout is likely to add differentiated capability for complex braided and formed biomedical structures to the company's existing product portfolio.

Integer Holdings (ITGR) Boosts Product Line with New Buyout

PLANO, Texas, Oct.  07, 2019  (GLOBE NEWSWIRE) -- Integer Holdings Corporation (“Integer”) (NYSE:ITGR), a leading medical device outsource manufacturer, today announced it has purchased certain assets of US BioDesign, a manufacturer of complex braided biomedical structures for disposable and implantable medical devices headquartered in Quakertown, Pa. The acquisition will add differentiated capability for complex braided and formed biomedical structures to Integer’s broad portfolio, further positioning Integer as a partner of choice for innovative medical technologies.

Integer Announces Acquisition of US BioDesign Assets

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Integer (ITGR) Stock?

Integer (ITGR) reported earnings 30 days ago. What's next for the stock?

Integer (ITGR) Down 18% Since Last Earnings Report: Can It Rebound?

Are Investors Undervaluing Integer (ITGR) Right Now?

Higher revenues and strong 2019 outlook benefit Integer Holdings' (ITGR) Q2 earnings.

Integer Holdings (ITGR) Q2 Earnings Beat, Revenues Miss

Integer (ITGR) delivered earnings and revenue surprises of 16.04% and -1.69%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Integer (ITGR) Tops Q2 Earnings Estimates (Revised)

Integer Holdings Corporation (ITGR) CEO Joe Dziedzic on Q2 2019 Results - Earnings Call Transcript

Integer (ITGR) delivered earnings and revenue surprises of 110.38% and -1.69%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Integer (ITGR) Tops Q2 Earnings Estimates

Integer (ITGR) Reports Next Week: What to Know Ahead of the Release

Why Is Integer (ITGR) Down 1.7% Since Last Earnings Report?

Integer Holdings Corporation (ITGR) CEO Joe Dziedzic on Q1 2019 Results - Earnings Call Transcript

Integer (ITGR) delivered earnings and revenue surprises of 25.00% and 3.48%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Integer (ITGR) Beats Q1 Earnings and Revenue Estimates

Better-than-expected performance at C&V and Cardiac & Neuromodulation product lines and higher revenues might aid Integer Holdings (ITGR) in Q1. But decline in non-medical sales might be a dampener.

Integer Holdings (ITGR) Q1 Earnings: What's in the Cards?

Integer (ITGR) closed at $77.10 in the latest trading session, marking a +0.19% move from the prior day.

Integer (ITGR) Gains But Lags Market: What You Should Know

Integer strengthens its balance sheet by reducing its leverage ratio from 5.6X at the end of 2017 to 3.5X at 2018 end.

Integer Holdings Gets Positive Outlook & B+ Rating From S&P

Teladoc

Both of these companies highlight their adjusted EBITDA growth while economic earnings reveal growing losses.

Danger Zone: Incentivizing Executives with Adjusted EBITDA

Integer (ITGR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Integer (ITGR) Down 2.4% Since Last Earnings Report: Can It Rebound?

Integer (ITGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

News for Integer Holdings Stock (ITGR)